Yüklüyor......
Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients
Dr Jordi Bruix* speaks to Laura Dormer, Editorial Director: Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research...
Kaydedildi:
| Yayımlandı: | Hepat Oncol |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Future Medicine Ltd
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095319/ https://ncbi.nlm.nih.gov/pubmed/30191039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0007 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|